Seeking better outcomes for patients
CytRx Corporation is a biopharmaceutical company focused on the discovery and development of new therapeutics to treat patients with high unmet medical needs
CytRx has potential milestone/royalty payments and an oncology subsidiary, Centurion BioPharma
CytRx milestones and royalties from Orphazyme for Arimoclomol
Orphazyme preparing for commercialization in 2022 for arimoclomol
CytRx potential milestones and royalties from ImmunityBio for aldoxorubicin
CytRx partnered Pipeline with ImmunityBio - aldoxorubicin
